— Blinded knowledge from the continued Part 2 scientific trial of BRTX-100 to be described in poster presentation —
— Firm to host webcasted convention name to evaluation knowledge on February 5, 2024 at 8:30am EST —
MELVILLE, N.Y., Feb. 01, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Firm”) (NASDAQ:BRTX), a scientific stage firm centered on stem cell-based therapies, in the present day introduced that preliminary 26–52 week blinded knowledge from the continued Part 2 scientific trial of BRTX-100 in topics with power lumbar disc illness (“cLDD”) can be offered by Francisco Silva, Vice President of Analysis and Growth, on the Orthopaedic Analysis Society (ORS) 2024 Annual Assembly, happening February 2-6, 2024 in Lengthy Seashore, California.
BRTX-100, a novel cell-based therapeutic engineered to focus on areas of the physique which have little blood circulate, is the Firm’s lead scientific candidate. The protection and efficacy of BRTX-100 in treating cLDD is being evaluated in a Part 2, potential, randomized, double-blinded and managed examine. A complete of as much as 99 eligible topics can be enrolled at as much as 16 scientific websites in america. Topics included within the trial can be randomized 2:1 to obtain both BRTX-100 or placebo.
The presentation, titled “Autologous Stem Cell Remedy for Power Lumbar Disc Illness, Preliminary Part 2 Medical Security and Feasibility Information of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells,” is scheduled for Sunday, February 4, 2024 between 10:15am-11:15am PST.
“We’re excited by this chance to share, for the very first time, preliminary knowledge from the continued Part 2 scientific trial of BRTX-100 within the therapy of cLDD,” stated Lance Alstodt, Chief Govt Officer of BioRestorative. “As curiosity within the potential scientific advantages of BRTX-100 grows, it is vital that we proceed to drive consciousness of this novel therapeutic candidate amongst researchers, regulators and clinicians via scientific displays at necessary conferences like ORS.”
Convention Name & Webcast Particulars
BioRestorative administration will host a webcasted convention name with an related slide presentation at 8:30am EST on Monday, February 5, 2024 to evaluation the BRTX-100 poster. To affix the convention name by way of cellphone and take part within the stay Q&A session, please dial 888-506-0062 (United States) or 973-528-0011 (Worldwide), participant entry code 234972. The stay webcast and audio archive of the presentation could also be accessed on the investor part of the BioRestorative web site at https://www.biorestorative.com/investor-relations/. An archived replay can be out there for about 90 days following the occasion.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic merchandise utilizing cell and tissue protocols, primarily involving grownup stem cells. Our two core packages, as described under, relate to the therapy of disc/spine illness and metabolic problems:
• Disc/Backbone Program (brtxDISC™): Our lead cell remedy candidate, BRTX-100, is a product formulated from autologous (or an individual’s personal) cultured mesenchymal stem cells collected from the affected person’s bone marrow. We intend that the product can be used for the non-surgical therapy of painful lumbosacral disc problems or as a complementary therapeutic to a surgical process. The BRTX-100 manufacturing course of makes use of proprietary expertise and entails gathering a affected person’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient process, BRTX-100 is to be injected by a doctor into the affected person’s broken disc. The therapy is meant for sufferers whose ache has not been alleviated by non-invasive procedures and who doubtlessly face the prospect of surgical procedure. We’ve got commenced a Part 2 scientific trial utilizing BRTX-100 to deal with power decrease again ache arising from degenerative disc illness.
• Metabolic Program (ThermoStem®): We’re creating a cell-based remedy candidate to focus on weight problems and metabolic problems utilizing brown adipose (fats) derived stem cells to generate brown adipose tissue (“BAT”). BAT is meant to imitate naturally occurring brown adipose depots that regulate metabolic homeostasis in people. Preliminary preclinical analysis signifies that elevated quantities of brown fats in animals could also be liable for extra caloric burning in addition to decreased glucose and lipid ranges. Researchers have discovered that folks with greater ranges of brown fats might have a decreased threat for weight problems and diabetes.
Ahead-Trying Statements
This press launch accommodates “forward-looking statements” inside the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended, and such forward-looking statements are made pursuant to the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. You might be cautioned that such statements are topic to a mess of dangers and uncertainties that might trigger future circumstances, occasions or outcomes to vary materially from these projected within the forward-looking statements on account of varied components and different dangers, together with, with out limitation, these set forth within the Firm’s newest Kind 10-Okay filed with the Securities and Alternate Fee. You need to take into account these components in evaluating the forward-looking statements included herein, and never place undue reliance on such statements. The forward-looking statements on this launch are made as of the date hereof and the Firm undertakes no obligation to replace such statements.
CONTACT:
E-mail: ir@biorestorative.com
Discussion about this post